Department of Medical Biochemistry, Semmelweis University, Budapest, Hungary.
Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2306-13. doi: 10.1161/ATVBAHA.111.229088. Epub 2011 Jul 7.
Arterial thrombi contain variable amounts of red blood cells (RBCs), which interact with fibrinogen through an eptifibatide-sensitive receptor and modify the structure of fibrin. In this study, we evaluated the modulator role of RBCs in the lytic susceptibility of fibrin.
If fibrin is formed at increasing RBC counts, scanning electron microscopy evidenced a decrease in fiber diameter from 150 to 96 nm at 40% (v/v) RBCs, an effect susceptible to eptifibatide inhibition (restoring 140 nm diameter). RBCs prolonged the lysis time in a homogeneous-phase fibrinolytic assay with tissue plasminogen activator (tPA) by up to 22.7±1.6%, but not in the presence of eptifibatide. Confocal laser microscopy using green fluorescent protein-labeled tPA and orange fluorescent fibrin showed that 20% to 40% (v/v) RBCs significantly slowed down the dissolution of the clots. The fluorescent tPA variant did not accumulate on the surface of fibrin containing RBCs at any cell count above 10%. The presence of RBCs in the clot suppressed the tPA-induced plasminogen activation, resulting in 45% less plasmin generated after 30 minutes of activation at 40% (v/v) RBCs.
RBCs confer lytic resistance to fibrin resulting from modified fibrin structure and impaired plasminogen activation through a mechanism that involves eptifibatide-sensitive fibrinogen-RBC interactions.
动脉血栓含有不同数量的红细胞(RBCs),它们通过依替巴肽敏感受体与纤维蛋白原相互作用,并改变纤维蛋白的结构。在这项研究中,我们评估了 RBC 在纤维蛋白溶解易感性中的调节剂作用。
如果纤维蛋白在 RBC 计数增加的情况下形成,扫描电子显微镜在 40%(v/v)RBC 时证明纤维直径从 150 纳米减小到 96 纳米,这一效应易受依替巴肽抑制(恢复到 140 纳米直径)。RBC 延长了组织型纤溶酶原激活剂(tPA)在均相纤维蛋白溶解测定中的溶解时间,最长可达 22.7±1.6%,但在依替巴肽存在下则没有。使用绿色荧光蛋白标记的 tPA 和橙色荧光纤维蛋白的共聚焦激光显微镜显示,20%至 40%(v/v)的 RBC 显著减缓了血栓的溶解。在任何高于 10%的细胞计数下,荧光 tPA 变体都不会在含有 RBC 的纤维蛋白表面积聚。在血栓中存在 RBC 会抑制 tPA 诱导的纤溶酶原激活,导致在 40%(v/v)RBC 下激活 30 分钟后产生的纤溶酶减少 45%。
RBC 通过涉及依替巴肽敏感纤维蛋白原-RBC 相互作用的机制,赋予纤维蛋白溶解抗性,从而导致纤维蛋白结构改变和纤溶酶原激活受损。